Neurotrophic factor secretion enhancement

Neurotrophic factor secretion enhancement" describes a therapeutic approach or scientific process in which the production and release of neurotrophic factors—such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), or neurotrophin-4 (NT-4)—is increased in relevant cells, primarily neurons[1][2][3][4][5][10]. Neurotrophic factors play crucial roles in neuronal survival, growth, differentiation, synaptic plasticity, and repair in both the developing and adult nervous system[4][5][6][8][9]. This process can be influenced by a broad range of internal (e.g., calcium signaling, gene expression changes) and external interventions (e.g., physical exercise, pharmacological agents, electrical activity)[1][3][7]. The enhancement of neurotrophic factor secretion represents a promising strategy for treating and modifying the course of neurodegenerative diseases (such as Alzheimer’s or Parkinson’s disease), depression, and other neurological disorders, but is *not itself a molecule, discrete molecular target, or receptor*. Rather, drugs and biologics act by increasing the levels or release of specific neurotrophic factors, or by activating their receptors (e.g., Trk family receptors, p75NTR), often engaging intracellular signaling pathways such as MAPK, PI3K, and PLC[2][4][6][10]. Because this phrase does not refer to a unique molecular entity, but to a therapeutic goal or pathway modulation, it *should not be treated as a canonical therapeutic target name or classified similarly*.